Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial (Q57484297)
Jump to navigation
Jump to search
article by Pierre Théroux et al published 4 May 2005 in European Heart Journal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial |
article by Pierre Théroux et al published 4 May 2005 in European Heart Journal |
Statements
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial (English)
0 references
4 May 2005
0 references
26
0 references
1964-1970
0 references
19
0 references